Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ACM Research, Inc. (ACMR)
|
Add to portfolio |
|
|
|
| Price: |
$80.58
| | Metrics |
| OS: |
59.9
|
M
| |
6
|
% ROE
|
| Market cap: |
$4.82
|
B
| |
9
|
% ROIC
|
|
|
|
| |
|
|
|
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
|
|
| |
|
|
|
|
|
| |
|
|
| EPS |
$0.80
| |
100.7
|
x P/E
|
|
BVPS
|
$13.92
| |
5.79
|
x P/B
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 388.8 | 259.8 | 156.6 | 107.5 | 74.6 | 0.0 | 27.4 | 31.2 |
| Revenue growth | 49.7% | 65.8% | 45.7% | 44.1% | | -100.0% | -12.3% | |
| Cost of goods sold | 205.2 | 144.9 | 87.0 | 56.9 | 40.2 | 0.0 | 14.0 | 17.1 |
| Gross profit | 183.6 | 114.9 | 69.6 | 50.7 | 34.4 | 0.0 | 13.3 | 14.1 |
| Gross margin | 47.2% | 44.2% | 44.4% | 47.1% | 46.2% | | 48.7% | 45.3% |
| Sales and marketing | 39.9 | 26.7 | 16.8 | 11.9 | 9.6 | 0.1 | 3.9 | 4.2 |
| Research and development | 62.2 | 34.2 | 19.1 | 12.9 | 10.4 | 0.1 | 3.3 | 2.9 |
| General and administrative | 22.5 | 15.2 | 12.2 | 8.1 | 8.0 | 1.5 | 2.7 | 2.1 |
| EBIT | 69.0 | 43.3 | 22.1 | 18.0 | 6.6 | 0.0 | 3.5 | 4.9 |
| EBIT margin | 17.7% | 16.7% | 14.1% | 16.7% | 8.8% | | 12.8% | 15.6% |
| Pre-tax income | 67.4 | 43.1 | 19.3 | 18.9 | 7.4 | 0.0 | 3.0 | 5.4 |
| Income taxes | 16.8 | 0.1 | -2.4 | -0.5 | 0.8 | 0.0 | 0.6 | -2.5 |
| Tax rate | 24.9% | 0.3% | | | 10.9% | | 20.0% | |
| Earnings from continuing ops | 39.2 | 37.8 | 18.8 | 18.9 | 6.6 | | 1.0 | 5.4 |
| Earnings from discontinued ops | 0.1 | | | | | | | |
| Net income | 39.3 | 37.8 | 18.8 | 18.9 | 6.6 | 0.0 | 1.0 | 5.4 |
| Net margin | 10.1% | 14.5% | 12.0% | 17.6% | 8.8% | | 3.8% | 17.2% |
| |
| Diluted EPS | $0.60 | $1.73 | $0.89 | $0.99 | $0.37 | | $0.27 | $1.71 |
| Shares outstanding (diluted) | 65.3 | 21.8 | 21.2 | 19.1 | 17.9 | | 3.8 | 3.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|